Does rituximab aggravate pre-existing hypogammaglobulinaemia?

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Rituximab is a chimeric anti-CD20 monoclonal antibody used in cancer therapy.
• It targets pre-B and mature B lymphocytes, causing transient B cell depletion.
• Typically, immunoglobulin levels remain unaffected due to sparing of stem cells and plasma cells.

Observation:

• Two adult patients with primary antibody deficiency developed recurrent infections post-rituximab treatment for idiopathic thrombocytopenic purpura (ITP).
• These patients had no prior significant infective issues despite other immunosuppressive treatments.
• Clinically significant immunodeficiency emerged weeks after rituximab administration, necessitating intravenous immunoglobulin replacement.

Findings:

• Rituximab administration was temporally linked to the onset of severe infections in these patients.
• The drug appears to have accelerated the clinical manifestation of underlying immune deficiency.
• This suggests a potential risk in patients with pre-existing antibody deficiencies.

Implications:

• Increased caution is advised when prescribing rituximab to patients with known or suspected primary antibody deficiencies.
• Further research is needed to understand the mechanisms behind rituximab-induced immunodeficiency acceleration.
• Enhanced monitoring for infections is crucial in vulnerable patient populations receiving immunomodulatory therapies.